Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Blood advances·2026
Same author

Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy.

Journal of comparative effectiveness research·2026
Same author

Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival.

Transplantation and cellular therapy·2026
Same author

Counterpoint: Bispecific antibodies are becoming the preferred standard of care in relapsed/refractory multiple myeloma.

Blood advances·2026
Same author

Real-World Incidence and Management of Non-Immune Effector Cell-Associated Neurotoxicity Syndrome Neurologic Events Following Ciltacabtagene Autoleucel in Multiple Myeloma.

Clinical epidemiology·2026
Same author

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis.

American journal of hematology·2026

Related Experiment Video

Updated: May 25, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma.

Murali Janakiram1, Venu K Thirukonda, Matthew Sullivan

  • 1Department of Oncology, Montefiore Medical Center, Bronx, NY, USA.

Current Treatment Options in Oncology
|February 3, 2012
PubMed
Summary

For Diffuse Large B-Cell Lymphoma (DLBCL), relapsed or refractory disease presents challenges. Novel targeted agents and clinical trials offer new hope for improving outcomes in these patients.

Related Experiment Videos

Last Updated: May 25, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Standard first-line treatment for Diffuse Large B-Cell Lymphoma (DLBCL) is Rituximab with chemotherapy.
  • Up to 40% of DLBCL patients experience relapsed or refractory disease despite initial treatment.
  • Many patients are ineligible for or do not respond to high-dose therapy with autologous stem cell transplant (HDT-ASCT).

Purpose of the Study:

  • To provide an opinion on optimal treatment strategies for relapsed/refractory DLBCL.
  • To highlight the potential of novel targeted agents based on recent molecular insights.
  • To advocate for the inclusion of relapsed/refractory DLBCL patients in clinical trials.

Main Methods:

  • Review of current treatment paradigms for DLBCL.
  • Discussion of advances in understanding DLBCL molecular subtypes and targeted pathways (e.g., Bcl-2, Bcl-6, B-Cell receptor, PI3K/Akt/mTOR).
  • Consideration of predictive markers for targeted therapy response (e.g., cell of origin, molecular profiling).

Main Results:

  • High-dose therapy with autologous stem cell transplant (HDT-ASCT) is considered optimal for responsive patients but is not universally applicable.
  • Emerging targeted agents show promise by addressing specific molecular pathways in DLBCL.
  • Successes and failures of novel agents are refining DLBCL classification and treatment individualization.

Conclusions:

  • Patients with relapsed/refractory DLBCL have a poor prognosis with no clear treatment consensus.
  • Novel targeted therapies, informed by molecular pathobiology, are crucial for improving outcomes.
  • Relapsed/refractory DLBCL patients are ideal candidates for clinical trials due to unmet needs and evolving treatment options.